RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016
Published Jun 30, 2016
60 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016, provides in depth analysis on RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1)
- The report reviews RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted the

  
Source:
Document ID
GMDHC0205TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Overview71
Therapeutics Development83
  RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Stage of Development81
  RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Therapy Area91
  RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Indication101
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Products under Development by Companies132
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Therapeutics Assessment156
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration172
  Assessment by Molecule Type192
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Companies Involved in Therapeutics Development219
  Basilea Pharmaceutica AG211
  Eli Lilly and Company221
  F. Hoffmann-La Roche Ltd.231
  Hanmi Pharmaceuticals, Co. Ltd.241
  Millennium Pharmaceuticals, Inc.251
  Novartis AG261
  Redx Pharma Plc271
  Sirnaomics, Inc.281
  VG Life Sciences, Inc.291
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Drug Profiles3015
  BAL-3833 Drug Profile302
  HM-95573 Drug Profile321
  hydroxychloroquine + sorafenib tosylate Drug Profile332
  LXH-254 Drug Profile351
  LY-3009120 Drug Profile362
  RG-7304 Drug Profile381
  Small Molecules to Inhibit Pan-RAF Kinase for Oncology Drug Profile391
  Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer Drug Profile401
  STP-503 Drug Profile411
  TAK-580 Drug Profile422
  TEW-0201 Drug Profile441
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Dormant Projects452
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Discontinued Products471
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Featured News &Press Releases4811
  Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting481
  Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting481
  Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent491
  Apr 22, 2015: Deciphera Pharmaceuticals Presents Data Highlighting pan-RAF inhibitor Cetuximab including Proprietary and Partnered Programs at AACR 2015 Annual Meeting491
  Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY3009120 at AACR Annual Meeting 2015501
  Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment511
  Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study511
  Apr 07, 2014: Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120521
  Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study531
  Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study531
  Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;541
  Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study551
  Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine551
  Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib561
  Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer572
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/RAF-Proto-Oncogene-Serine-Threonine-Protein-Kinase-C-Raf-Kinase-or-Proto-Oncogene-c-RAF-or-Raf-1-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16098>
  
APA:
Global Markets Direct - Market Research. (2016). RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/RAF-Proto-Oncogene-Serine-Threonine-Protein-Kinase-C-Raf-Kinase-or-Proto-Oncogene-c-RAF-or-Raf-1-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16098>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.